文献速递类风湿关节炎

难治性类风湿关节炎的特征:一项国际调查的结果

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.
PubMed 文献 · Ann Rheum Dis · 2018-09-07

该国际调查向风湿科医生发放问卷,以识别难治性类风湿关节炎(RA)的特征及当前管理建议未覆盖的问题。410名应答者中,50%以28关节疾病活动度评分>3.2或存在活动性疾病体征作为特征,89%选择无法将糖皮质激素减至每日泼尼松等效剂量5 mg或10 mg以下;结论认为难治性RA概念差异大,若干重要问题未被现行EULAR建议覆盖。

要点

  • 50%应答者以28关节疾病活动度评分>3.2或活动性疾病体征定义难治性RA。
  • 89%应答者选择无法将糖皮质激素减至每日泼尼松等效剂量5 mg或10 mg以下。
  • 干扰性合并症、关节外表现和多重用药被确定为现行管理建议遗漏的重要问题。

核心结论

  • 难治性RA的概念存在很大差异,若干关于这些患者的重要问题未被现行EULAR建议涉及。

研究设计与样本

  • 国际调查,向风湿科医生发放多选题和开放性问题,共410名应答者完成调查。

主要发现

  • 50%应答者选择28关节疾病活动度评分>3.2或存在提示活动性疾病的体征作为难治性RA的特征。
  • 42%应答者选择疲劳作为难治性RA的特征。
  • 48%应答者选择对≥2种传统合成改善病情抗风湿药(DMARDs)且≥2种生物/靶向合成DMARDs治疗失败作为难治性RA的特征。
  • 89%应答者选择无法将糖皮质激素减至每日泼尼松等效剂量5 mg或10 mg以下作为难治性RA的特征。
  • 干扰性合并症、关节外表现和多重用药被确定为现行管理建议中遗漏的重要问题。

关键数值与推荐

  • 50%应答者以28关节疾病活动度评分>3.2或活动性疾病体征作为难治性RA特征。
  • 48%应答者以对≥2种传统合成DMARDs且≥2种生物/靶向合成DMARDs治疗失败作为难治性RA特征。
  • 89%应答者以无法将糖皮质激素减至每日泼尼松等效剂量5 mg或10 mg以下作为难治性RA特征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with difficult-to-treat rheumatoid arthritis (RA) remain symptomatic despite treatment according to current European League Against Rheumatism (EULAR) management recommendations. These focus on early phases of the disease and pharmacological management. We aimed to identify characteristics of difficult-to-treat RA and issues to be addressed in its workup and management that are not covered by current management recommendations. METHODS: An international survey was conducted among rheumatologists with multiple-choice questions on disease characteristics of difficult-to-treat RA. Using open questions, additional items to be addressed and items missing in current management recommendations were identified. RESULTS: 410 respondents completed the survey: 50% selected disease activity score assessing 28 joints >3.2 OR presence of signs suggestive of active disease as characteristics of difficult-to-treat RA; 42% selected fatigue; 48% selected failure to ≥2 conventional synthetic disease-modifying antirheumatic drugs (DMARDs) AND ≥2 biological/targeted synthetic DMARDs; 89% selected inability to taper glucocorticoids below 5 mg or 10 mg prednisone equivalent daily. Interfering comorbidities, extra-articular manifestations and polypharmacy were identified as important issues missing in current management recommendations. CONCLUSIONS: There is wide variation in concepts of difficult-to-treat RA. Several important issues regarding these patients are not addressed by current EULAR recommendations.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Roodenrijs NMT, de Hair MJH, van der Goes MC, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018. PMID: 30194273. doi:10.1136/annrheumdis-2018-213687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。